Abstract

Previous studies have led to conflicting results regarding the effect of hesperidin supplementation on cardiometabolic markers. This study aimed to evaluate the efficacy of hesperidin supplementation on lipid profile and blood pressure through a systematic review and meta-analysis of randomized controlled trials (RCTs). PubMed, Web of Science, Scopus, and Google Scholar, as well as the reference lists of the identified relevant RCTs, were searched up to May 2018. Effect sizes were pooled by using the random effects model. Ten RCTs (577 participants) were eligible to be included in the systematic review. The meta-analysis revealed that hesperidin supplementation had no effect on serum total cholesterol (weighted mean difference WMD = -1.04 mg/dl; 95% confidence interval CI: -5.65, 3.57), low-density lipoprotein cholesterol (WMD = -1.96 mg/dl; 95% CI -7.56, 3.64), high-density lipoprotein cholesterol (WMD = 0.16 mg/dl; 95% CI -1.94, 2.28), and triglyceride (WMD = 0.69 mg/dl; 95% CI -5.91, 7.30), with no significant between-study heterogeneity. Hesperidin supplement also had no effect on systolic (WMD = -0.85 mmHg; 95% CI -3.07, 1.36) and diastolic blood pressure (WMD = -0.48 mmHg; 95% CI -2.39, 1.42). Hesperidin supplementation might not improve lipid profile and blood pressure. Future well-designed trials are still needed to confirm these results.